98 related articles for article (PubMed ID: 11761226)
1. Transgenic animal models that might be useful in identifying unsuspected oncogenic factors in tumour cell substrates.
Sistare FD
Dev Biol (Basel); 2001; 106():123-31; discussion 131-2, 143-60. PubMed ID: 11761226
[TBL] [Abstract][Full Text] [Related]
2. The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI.
MacDonald J; French JE; Gerson RJ; Goodman J; Inoue T; Jacobs A; Kasper P; Keller D; Lavin A; Long G; McCullough B; Sistare FD; Storer R; van der Laan JW
Toxicol Sci; 2004 Feb; 77(2):188-94. PubMed ID: 14657512
[TBL] [Abstract][Full Text] [Related]
3. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
4. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
Gaylor DW
Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
[TBL] [Abstract][Full Text] [Related]
5. Animal models of neoplastic development.
Pitot HC
Dev Biol (Basel); 2001; 106():53-7; discussion 57-9, 143-60. PubMed ID: 11761267
[TBL] [Abstract][Full Text] [Related]
6. Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: approaches to dose selection.
Rhomberg LR; Baetcke K; Blancato J; Bus J; Cohen S; Conolly R; Dixit R; Doe J; Ekelman K; Fenner-Crisp P; Harvey P; Hattis D; Jacobs A; Jacobson-Kram D; Lewandowski T; Liteplo R; Pelkonen O; Rice J; Somers D; Turturro A; West W; Olin S
Crit Rev Toxicol; 2007; 37(9):729-837. PubMed ID: 17957539
[TBL] [Abstract][Full Text] [Related]
7. The transgenic mouse assay as an alternative test method for regulatory carcinogenicity studies--implications for REACH.
Wells MY; Williams ES
Regul Toxicol Pharmacol; 2009 Mar; 53(2):150-5. PubMed ID: 19126422
[TBL] [Abstract][Full Text] [Related]
8. Experimental bladder carcinogenesis-rodent models.
Oliveira PA; Colaco A; De la Cruz P LF; Lopes C
Exp Oncol; 2006 Mar; 28(1):2-11. PubMed ID: 16614700
[TBL] [Abstract][Full Text] [Related]
9. Safety characterization of HeLa-based cell substrates used in the manufacture of a recombinant adeno-associated virus-HIV vaccine.
Tatalick LM; Gerard CJ; Takeya R; Price DN; Thorne BA; Wyatt LM; Anklesaria P
Vaccine; 2005 Apr; 23(20):2628-38. PubMed ID: 15780446
[TBL] [Abstract][Full Text] [Related]
10. Use of genetically modified mouse models for evaluation of carcinogenic risk: considerations for the laboratory animal scientist.
Recio L; Everitt J
Comp Med; 2001 Oct; 51(5):399-405. PubMed ID: 11924798
[TBL] [Abstract][Full Text] [Related]
11. Review article: How useful are the rodent animal models of gastric adenocarcinoma?
Pritchard DM; Przemeck SM
Aliment Pharmacol Ther; 2004 Apr; 19(8):841-59. PubMed ID: 15080846
[TBL] [Abstract][Full Text] [Related]
12. The utility of the K6/ODC transgenic mouse as an alternative short term dermal model for carcinogenicity testing of pharmaceuticals.
Miller TJ; Honchel R; Espandiari P; Knapton A; Zhang J; Sistare FD; Hanig JP
Regul Toxicol Pharmacol; 2008 Feb; 50(1):87-97. PubMed ID: 18069108
[TBL] [Abstract][Full Text] [Related]
13. NTP Comparative Initiation/Promotion Skin Paint Studies of B6C3F1 Mice, Swiss (CD-1(R)) Mice, and SENCAR Mice.
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Feb; 441():1-201. PubMed ID: 12595922
[TBL] [Abstract][Full Text] [Related]
14. Environmental and chemical carcinogenesis.
Wogan GN; Hecht SS; Felton JS; Conney AH; Loeb LA
Semin Cancer Biol; 2004 Dec; 14(6):473-86. PubMed ID: 15489140
[TBL] [Abstract][Full Text] [Related]
15. Mouse models for human head and neck squamous cell carcinomas.
Lu SL; Herrington H; Wang XJ
Head Neck; 2006 Oct; 28(10):945-54. PubMed ID: 16721744
[TBL] [Abstract][Full Text] [Related]
16. Modulators of carcinogenesis.
Munro IC; Lynch BS; Kittur A; Nestmann ER
Regul Toxicol Pharmacol; 1995 Feb; 21(1):60-70; discussion 81-6. PubMed ID: 7784637
[TBL] [Abstract][Full Text] [Related]
17. Cancer risk assessment for 1,3-butadiene: data integration opportunities.
Preston RJ
Chem Biol Interact; 2007 Mar; 166(1-3):150-5. PubMed ID: 16647696
[TBL] [Abstract][Full Text] [Related]
18. Current and future approaches using genetically modified mice in endocrine research.
Davey RA; MacLean HE
Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E429-38. PubMed ID: 16684850
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Xpa-deficient transgenic mouse model for short-term carcinogenicity testing: 9-month studies with haloperidol, reserpine, phenacetin, and D-mannitol.
Lina BA; Woutersen RA; Bruijntjes JP; van Benthem J; van den Berg JA; Monbaliu J; Thoolen BJ; Beems RB; van Kreijl CF
Toxicol Pathol; 2004; 32(2):192-201. PubMed ID: 15200157
[TBL] [Abstract][Full Text] [Related]
20. Transgenic mice as an in vivo model of lymphomagenesis.
Tarantul VZ
Int Rev Cytol; 2004; 236():123-80. PubMed ID: 15261738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
